Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

This publication has 6 references indexed in Scilit:

• EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLoS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
  Science, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004